Cytokinetics, Incorporated – Product Pipeline Review – 2013
Summary
Global Market Direct’s pharmaceuticals report, “Cytokinetics, Incorporated - Product Pipeline Review - 2013” provides data on the Cytokinetics, Incorporated’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Cytokinetics, Incorporated’s corporate website, SEC filings, investor presentations and featured press releases, both from Cytokinetics, Incorporated and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Summary
Global Market Direct’s pharmaceuticals report, “Cytokinetics, Incorporated - Product Pipeline Review - 2013” provides data on the Cytokinetics, Incorporated’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Cytokinetics, Incorporated’s corporate website, SEC filings, investor presentations and featured press releases, both from Cytokinetics, Incorporated and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Cytokinetics, Incorporated - Brief Cytokinetics, Incorporated overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Cytokinetics, Incorporated human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Cytokinetics, Incorporated with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Cytokinetics, Incorporated’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate Cytokinetics, Incorporated’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Cytokinetics, Incorporated in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Cytokinetics, Incorporated’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Cytokinetics, Incorporated.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Cytokinetics, Incorporated and identify potential opportunities in those areas.
Cytokinetics, Incorporated Snapshot
Cytokinetics, Incorporated Overview
Key Information
Key Facts
Cytokinetics, Incorporated – Research and Development Overview
Key Therapeutic Areas
Cytokinetics, Incorporated – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Cytokinetics, Incorporated – Pipeline Products Glance
Cytokinetics, Incorporated Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Cytokinetics, Incorporated – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Cytokinetics, Incorporated – Drug Profiles
CK-2018488
Product Description
Mechanism of Action
R&D Progress
CK-2018509
Product Description
Mechanism of Action
R&D Progress
CK-2018571
Product Description
Mechanism of Action
R&D Progress
CK-2019165
Product Description
Mechanism of Action
R&D Progress
CK-2066260
Product Description
Mechanism of Action
R&D Progress
CK-2127107
Product Description
Mechanism of Action
R&D Progress
GSK-923295
Product Description
Mechanism of Action
R&D Progress
ispinesib
Product Description
Mechanism of Action
R&D Progress
Myosin Inhibitor
Product Description
Mechanism of Action
R&D Progress
omecamtiv mecarbil
Product Description
Mechanism of Action
R&D Progress
tirasemtiv
Product Description
Mechanism of Action
R&D Progress
Cytokinetics, Incorporated – Pipeline Analysis
Cytokinetics, Incorporated – Pipeline Products by Therapeutic Class
Cytokinetics, Incorporated – Pipeline Products by Route of Administration
Cytokinetics, Incorporated – Pipeline Products By Mechanism of Action
Cytokinetics, Incorporated – Recent Pipeline Updates
Cytokinetics, Incorporated - Dormant Projects
Cytokinetics, Incorporated – Company Statement
Cytokinetics, Incorporated – Locations And Subsidiaries
Head Office
Cytokinetics, Incorporated, Recent Developments
Cytokinetics, Incorporated- Press Release
Apr 04, 2013: Cytokinetics Receives Grant From Families With Spinal Muscular Atrophy For Preclinical Development Of Tirasemtiv
Mar 21, 2013: Cytokinetics Announces Presentation Of Phase IIA Clinical Trial Data Of Tirasemtiv In Patients With Myasthenia Gravis
Mar 18, 2013: Cytokinetics Announces Update To Heart Failure Program
Mar 13, 2013: Cytokinetics Announces Presentation Of Phase IIa Trial Data On Tirasemtiv At 65th AAN Annual Meeting
Feb 12, 2013: Cytokinetics Opens Phase II Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
Dec 13, 2010: Cytokinetics Announces Successful Completion Of Phase II “Evidence Of Effect” Clinical Trial Of Ck-2017357 In Patients With Amyotrophic Lateral Sclerosis
Dec 07, 2010: Cytokinetics To Present Phase IIa Clinical Trial Data Relating To CK-2017357 At International Symposium On ALS/MND
Oct 27, 2010: Cytokinetics Reports Selection Of CK-2017357 To Windhover's Top 10 HOT SPACE Projects To Watch List
Oct 01, 2010: Cytokinetics Presents Clinical And Non-Clinical Data Relating To CK-2017357 At Annual Aging Muscle Symposium
Sep 28, 2010: Cytokinetics To Present Clinical And Non-Clinical Data Of CK-2017357 At Annual Aging Muscle Symposium
Sep 21, 2010: Cytokinetics Provides Update Regarding Omecamtiv Mecarbil Clinical Development Program
Sep 14, 2010: Cytokinetics Presents Phase I Clinical Trial Data On Omecamtiv Mecarbil At 2010 Heart Failure Society Of America Annual Meeting
Jul 26, 2010: Cytokinetics Receives $2.9 Million For Preclinical And Clinical Development Of CK-2017357 In Myasthenia Gravis
Jul 22, 2010: Cytokinetics Presents Phase I Data Relating To CK-2017357 At XII International Congress On Neuromuscular Diseases
Jul 14, 2010: Cytokinetics To Present Phase I Data Relating To CK-2017357 At XII International Congress On Neuromuscular Diseases
May 27, 2010: Cytokinetics Announces Opening Of Phase IIa EoE Trial Of CK-2017357 In Patients With Peripheral Artery Disease And Claudication
May 18, 2010: Cytokinetics Presents Non-Clinical Data From Smooth Muscle Contractility Program
Apr 28, 2010: Cytokinetics Announces Presentation Of Non-Clinical Data Relating To CK-2017357 At Society For Vascular Medicine's 2010 Annual Meeting
Mar 22, 2010: Cytokinetics Initiates Phase IIa Evidence Of Effect Clinical Trial Of CK-2017357 For Patients With ALS
Mar 11, 2010: Cytokinetics Receives Orphan Drug Designation For CK-2017357 For Treatment Of ALS
Jan 27, 2010: Cytokinetics Announces Phase I Clinical Trial Results Of CK-2017357
Jan 11, 2010: Cytokinetics Announces Positive Data From Phase I Clinical Trial Of CK-2017357 For The Treatment Of Aging, Muscle Wasting Or Neuromuscular Dysfunction
Financial Deals Landscape
Cytokinetics, Incorporated, Deals Summary
Cytokinetics, Incorporated, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Cytokinetics Extends Research Agreement With GlaxoSmithKline
Cytokinetics Extends Its Research Collaboration With GlaxoSmithKline
Cytokinetics Signs Strategic Agreement With Amgen
Licensing Agreements
Cytokinetics Enters Into Licensing Agreement With MyoKardia For Cardiac Sarcomere Inhibitor
Amgen Enters Into A Licensing Agreement With Cytokinetics
Equity Offering
Cytokinetics Completes Public Offering Of Shares For $5 Million
Cytokinetics Completes Public Offering Of Common Stock And Warrants For $42.5 Million
Cytokinetics Completes Public Offering Of Preferred Stock And Warrants For $17.5 Million
Cytokinetics Completes Private Placement Of Common Stock For $8 Million
Cytokinetics Completes Private Placement Of Series A Convertible Preferred Stock For $12.1 Million
Cytokinetics Completes Registered Direct Offering Of $14 Million
Cytokinetics Completes Private Placement Of $6.9 Million
Cytokinetics Completes Private Placement Of $1.8 Million
Cytokinetics Completes Private Placement Of $7.8 Million
Cytokinetics Completes Private Placement Of $33 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Cytokinetics, Incorporated, Key Information
Cytokinetics, Incorporated, Key Facts
Cytokinetics, Incorporated – Pipeline by Indication, 2013
Cytokinetics, Incorporated – Pipeline by Stage of Development, 2013
Cytokinetics, Incorporated – Monotherapy Products in Pipeline, 2013
Cytokinetics, Incorporated – Phase II, 2013
Cytokinetics, Incorporated – Phase I, 2013
Cytokinetics, Incorporated – Pre-Clinical, 2013
Cytokinetics, Incorporated – Pipeline By Therapeutic Class, 2013
Cytokinetics, Incorporated – Pipeline By Route of Administration, 2013
Cytokinetics, Incorporated – Pipeline Products By Mechanism of Action, 2013
Cytokinetics, Incorporated – Recent Pipeline Updates, 2013
Cytokinetics, Incorporated - Dormant Developmental Projects,2013
Cytokinetics, Incorporated, Deals Summary
Cytokinetics Extends Research Agreement With GlaxoSmithKline
Cytokinetics Extends Its Research Collaboration With GlaxoSmithKline
Cytokinetics Signs Strategic Agreement With Amgen
Cytokinetics Enters Into Licensing Agreement With MyoKardia For Cardiac Sarcomere Inhibitor
Amgen Enters Into A Licensing Agreement With Cytokinetics
Cytokinetics Completes Public Offering Of Shares For $5 Million
Cytokinetics Completes Public Offering Of Common Stock And Warrants For $42.5 Million
Cytokinetics Completes Public Offering Of Preferred Stock And Warrants For $17.5 Million
Cytokinetics Completes Private Placement Of Common Stock For $8 Million
Cytokinetics Completes Private Placement Of Series A Convertible Preferred Stock For $12.1 Million
Cytokinetics Completes Registered Direct Offering Of $14 Million
Cytokinetics Completes Private Placement Of $6.9 Million
Cytokinetics Completes Private Placement Of $1.8 Million
Cytokinetics Completes Private Placement Of $7.8 Million
Cytokinetics Completes Private Placement Of $33 Million
LIST OF FIGURES
Cytokinetics, Incorporated – Pipeline by Indication, 2013
Cytokinetics, Incorporated – Pipeline by Stage of Development, 2013
Cytokinetics, Incorporated – Monotherapy Products in Pipeline, 2013
Cytokinetics, Incorporated – Pipeline By Therapeutic Class, 2013
Cytokinetics, Incorporated – Pipeline By Route of Administration, 2013
Cytokinetics, Incorporated - Pipeline Products By Mechanism of Action, 2013
Cytokinetics, Incorporated Overview
Key Information
Key Facts
Cytokinetics, Incorporated – Research and Development Overview
Key Therapeutic Areas
Cytokinetics, Incorporated – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Cytokinetics, Incorporated – Pipeline Products Glance
Cytokinetics, Incorporated Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Cytokinetics, Incorporated – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Cytokinetics, Incorporated – Drug Profiles
CK-2018488
Product Description
Mechanism of Action
R&D Progress
CK-2018509
Product Description
Mechanism of Action
R&D Progress
CK-2018571
Product Description
Mechanism of Action
R&D Progress
CK-2019165
Product Description
Mechanism of Action
R&D Progress
CK-2066260
Product Description
Mechanism of Action
R&D Progress
CK-2127107
Product Description
Mechanism of Action
R&D Progress
GSK-923295
Product Description
Mechanism of Action
R&D Progress
ispinesib
Product Description
Mechanism of Action
R&D Progress
Myosin Inhibitor
Product Description
Mechanism of Action
R&D Progress
omecamtiv mecarbil
Product Description
Mechanism of Action
R&D Progress
tirasemtiv
Product Description
Mechanism of Action
R&D Progress
Cytokinetics, Incorporated – Pipeline Analysis
Cytokinetics, Incorporated – Pipeline Products by Therapeutic Class
Cytokinetics, Incorporated – Pipeline Products by Route of Administration
Cytokinetics, Incorporated – Pipeline Products By Mechanism of Action
Cytokinetics, Incorporated – Recent Pipeline Updates
Cytokinetics, Incorporated - Dormant Projects
Cytokinetics, Incorporated – Company Statement
Cytokinetics, Incorporated – Locations And Subsidiaries
Head Office
Cytokinetics, Incorporated, Recent Developments
Cytokinetics, Incorporated- Press Release
Apr 04, 2013: Cytokinetics Receives Grant From Families With Spinal Muscular Atrophy For Preclinical Development Of Tirasemtiv
Mar 21, 2013: Cytokinetics Announces Presentation Of Phase IIA Clinical Trial Data Of Tirasemtiv In Patients With Myasthenia Gravis
Mar 18, 2013: Cytokinetics Announces Update To Heart Failure Program
Mar 13, 2013: Cytokinetics Announces Presentation Of Phase IIa Trial Data On Tirasemtiv At 65th AAN Annual Meeting
Feb 12, 2013: Cytokinetics Opens Phase II Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
Dec 13, 2010: Cytokinetics Announces Successful Completion Of Phase II “Evidence Of Effect” Clinical Trial Of Ck-2017357 In Patients With Amyotrophic Lateral Sclerosis
Dec 07, 2010: Cytokinetics To Present Phase IIa Clinical Trial Data Relating To CK-2017357 At International Symposium On ALS/MND
Oct 27, 2010: Cytokinetics Reports Selection Of CK-2017357 To Windhover's Top 10 HOT SPACE Projects To Watch List
Oct 01, 2010: Cytokinetics Presents Clinical And Non-Clinical Data Relating To CK-2017357 At Annual Aging Muscle Symposium
Sep 28, 2010: Cytokinetics To Present Clinical And Non-Clinical Data Of CK-2017357 At Annual Aging Muscle Symposium
Sep 21, 2010: Cytokinetics Provides Update Regarding Omecamtiv Mecarbil Clinical Development Program
Sep 14, 2010: Cytokinetics Presents Phase I Clinical Trial Data On Omecamtiv Mecarbil At 2010 Heart Failure Society Of America Annual Meeting
Jul 26, 2010: Cytokinetics Receives $2.9 Million For Preclinical And Clinical Development Of CK-2017357 In Myasthenia Gravis
Jul 22, 2010: Cytokinetics Presents Phase I Data Relating To CK-2017357 At XII International Congress On Neuromuscular Diseases
Jul 14, 2010: Cytokinetics To Present Phase I Data Relating To CK-2017357 At XII International Congress On Neuromuscular Diseases
May 27, 2010: Cytokinetics Announces Opening Of Phase IIa EoE Trial Of CK-2017357 In Patients With Peripheral Artery Disease And Claudication
May 18, 2010: Cytokinetics Presents Non-Clinical Data From Smooth Muscle Contractility Program
Apr 28, 2010: Cytokinetics Announces Presentation Of Non-Clinical Data Relating To CK-2017357 At Society For Vascular Medicine's 2010 Annual Meeting
Mar 22, 2010: Cytokinetics Initiates Phase IIa Evidence Of Effect Clinical Trial Of CK-2017357 For Patients With ALS
Mar 11, 2010: Cytokinetics Receives Orphan Drug Designation For CK-2017357 For Treatment Of ALS
Jan 27, 2010: Cytokinetics Announces Phase I Clinical Trial Results Of CK-2017357
Jan 11, 2010: Cytokinetics Announces Positive Data From Phase I Clinical Trial Of CK-2017357 For The Treatment Of Aging, Muscle Wasting Or Neuromuscular Dysfunction
Financial Deals Landscape
Cytokinetics, Incorporated, Deals Summary
Cytokinetics, Incorporated, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Cytokinetics Extends Research Agreement With GlaxoSmithKline
Cytokinetics Extends Its Research Collaboration With GlaxoSmithKline
Cytokinetics Signs Strategic Agreement With Amgen
Licensing Agreements
Cytokinetics Enters Into Licensing Agreement With MyoKardia For Cardiac Sarcomere Inhibitor
Amgen Enters Into A Licensing Agreement With Cytokinetics
Equity Offering
Cytokinetics Completes Public Offering Of Shares For $5 Million
Cytokinetics Completes Public Offering Of Common Stock And Warrants For $42.5 Million
Cytokinetics Completes Public Offering Of Preferred Stock And Warrants For $17.5 Million
Cytokinetics Completes Private Placement Of Common Stock For $8 Million
Cytokinetics Completes Private Placement Of Series A Convertible Preferred Stock For $12.1 Million
Cytokinetics Completes Registered Direct Offering Of $14 Million
Cytokinetics Completes Private Placement Of $6.9 Million
Cytokinetics Completes Private Placement Of $1.8 Million
Cytokinetics Completes Private Placement Of $7.8 Million
Cytokinetics Completes Private Placement Of $33 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Cytokinetics, Incorporated, Key Information
Cytokinetics, Incorporated, Key Facts
Cytokinetics, Incorporated – Pipeline by Indication, 2013
Cytokinetics, Incorporated – Pipeline by Stage of Development, 2013
Cytokinetics, Incorporated – Monotherapy Products in Pipeline, 2013
Cytokinetics, Incorporated – Phase II, 2013
Cytokinetics, Incorporated – Phase I, 2013
Cytokinetics, Incorporated – Pre-Clinical, 2013
Cytokinetics, Incorporated – Pipeline By Therapeutic Class, 2013
Cytokinetics, Incorporated – Pipeline By Route of Administration, 2013
Cytokinetics, Incorporated – Pipeline Products By Mechanism of Action, 2013
Cytokinetics, Incorporated – Recent Pipeline Updates, 2013
Cytokinetics, Incorporated - Dormant Developmental Projects,2013
Cytokinetics, Incorporated, Deals Summary
Cytokinetics Extends Research Agreement With GlaxoSmithKline
Cytokinetics Extends Its Research Collaboration With GlaxoSmithKline
Cytokinetics Signs Strategic Agreement With Amgen
Cytokinetics Enters Into Licensing Agreement With MyoKardia For Cardiac Sarcomere Inhibitor
Amgen Enters Into A Licensing Agreement With Cytokinetics
Cytokinetics Completes Public Offering Of Shares For $5 Million
Cytokinetics Completes Public Offering Of Common Stock And Warrants For $42.5 Million
Cytokinetics Completes Public Offering Of Preferred Stock And Warrants For $17.5 Million
Cytokinetics Completes Private Placement Of Common Stock For $8 Million
Cytokinetics Completes Private Placement Of Series A Convertible Preferred Stock For $12.1 Million
Cytokinetics Completes Registered Direct Offering Of $14 Million
Cytokinetics Completes Private Placement Of $6.9 Million
Cytokinetics Completes Private Placement Of $1.8 Million
Cytokinetics Completes Private Placement Of $7.8 Million
Cytokinetics Completes Private Placement Of $33 Million
LIST OF FIGURES
Cytokinetics, Incorporated – Pipeline by Indication, 2013
Cytokinetics, Incorporated – Pipeline by Stage of Development, 2013
Cytokinetics, Incorporated – Monotherapy Products in Pipeline, 2013
Cytokinetics, Incorporated – Pipeline By Therapeutic Class, 2013
Cytokinetics, Incorporated – Pipeline By Route of Administration, 2013
Cytokinetics, Incorporated - Pipeline Products By Mechanism of Action, 2013
